Agios Pharma stock raised to Outperform

On Thursday, Agios Pharmaceuticals (NASDAQ:AGIO), a biopharmaceutical company, received an Outperform rating from Raymond James, along with a new price target of $51.00. The firm's coverage on Agios Pharma (NASDAQ:AGIO) was resumed, focusing on the potential of the company's sickle cell disease (SCD) treatment. The analyst noted the absence of Oxbryta, a competing drug recently withdrawn from the market by Pfizer (NYSE:PFE), has left a significant commercial opportunity for Agios Pharma's SCD therapy.

Agios Pharma's treatment for SCD is currently viewed as a high-risk trial, especially due to its (co)-primary endpoint of vaso-occlusive crises (VoC). However, the analyst believes the mechanism of action (MoA) for Agios Pharma's drug, mitapivat, is distinct from that of Oxbryta, which could be advantageous. Recent checks with Key Opinion Leaders (KOLs) suggest that mitapivat's hemoglobin benefits are more likely to translate into VoC relief compared to Oxbryta.

The withdrawal of Oxbryta from the market has notably opened up the commercial landscape for SCD treatments, which Agios Pharma is now positioned to capitalize on. With the upcoming readout expected next year, the analyst from Raymond James sees a favorable risk/reward balance for Agios Pharma's stock and has recommended a buy.

The price target of $51.00 set by Raymond James represents a positive outlook on the stock's future performance. Agios Pharma's progress in developing its SCD treatment and the market dynamics following the withdrawal of a key competitor are key factors in this assessment. Investors and market watchers will be looking forward to the trial readout next year to see if the company can fulfill these expectations.

In other recent news, Agios Pharma has been the subject of several significant developments. Leerink Partners downgraded Agios Pharma's stock from Outperform to Market Perform due to safety concerns for a rival drug, Oxbryta, by Pfizer.

The withdrawal of Oxbryta has raised questions about the potential risks associated with Agios Pharma's own treatment, mitapivat. However, this could also provide an opportunity for Agios Pharma to capture market share in the sickle cell disease space, provided that mitapivat proves successful and safe.

Additionally, the U.S. Food and Drug Administration granted Agios Pharma an orphan drug designation for tebapivat, intended for the treatment of myelodysplastic syndromes. The company also reported positive results from its Phase 3 ENERGIZE-T study of mitapivat, marking it as the first oral disease-modifying treatment effective in transfusion-dependent thalassemia.

On the financial front, Agios announced a lucrative deal with Royalty Pharma involving the sale of rights to a royalty on potential U.S. net sales of Vorasidenib. The company also entered into a distribution agreement with NewBridge Pharmaceuticals for commercializing mitapivat outside the U.S.

Piper Sandler maintained an Overweight rating on Agios Pharma shares based on a promising outlook for the uptake of mitapivat and Casgevy in treating thalassemia and sickle cell disease. RBC Capital adjusted its outlook on Agios, raising the price target to $55 from $53, while maintaining an Outperform rating.

InvestingPro Insights

Agios Pharmaceuticals' financial metrics and market performance offer additional context to the Raymond James analyst's optimistic outlook. According to InvestingPro data, the company's revenue growth has been robust, with a 55.39% increase over the last twelve months as of Q2 2024. This growth trajectory aligns with the potential market opportunity highlighted in the article, especially given the withdrawal of a competing drug.

InvestingPro Tips reveal that Agios holds more cash than debt on its balance sheet, which could provide financial flexibility as the company advances its sickle cell disease treatment. Additionally, analysts predict that the company will be profitable this year, potentially marking a significant milestone for Agios.

The stock has shown strong performance, with a 72.02% price total return over the past year and a substantial 83.61% return year-to-date. This positive momentum may reflect investor confidence in Agios' pipeline and market potential, particularly in light of the expanded commercial opportunity in the SCD treatment space.

For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for Agios Pharmaceuticals, providing deeper insights into the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.